# AbbVie Buys Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline

> ma · REPORTED · 2026-06-22

AbbVie announced on June 22, 2026 an all-cash acquisition of Apogee Therapeutics for approximately $10.9 billion ($135.11 per share, a 49% premium), centering on zumilokibart (APG777), a half-life-extended anti-IL-13 antibody in Phase 3 for atopic dermatitis, plus a dual IL-13/TSLP combination candidate. The deal expands AbbVie's post-Humira immunology portfolio.

- Company: AbbVie / Apogee Therapeutics
- Sector: therapeutics
- Primary source: https://lifesciencedaily.news/life-science-news-29-june-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.